Seminars in Oncology
Volume 33, Issue 2 , Pages 220-229 , April 2006

Vaccine- and Immune-Based Therapy in Chronic Lymphocytic Leukemia

  • Rifca Le Dieu
    • ,
  • John Gribben

      Affiliations

    • Corresponding Author InformationAddress correspondence to John Gribben, MD, DSc, Institute of Cancer, CRUK Medical Oncology Unit, Barts and The London School of Medicine, Queen Mary, University of London, Charterhouse Square, London EC1M 6BQ, UK.

References 

  1. Hewitt HB , Blake ER , Walder AS . A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumors of spontaneous origin . Br J Cancer . 1976;33:241–259
  2. Rosenberg SA , Lotze MT , Muul LM , et al.   Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer . N Engl J Med . 1985;313:1485–1492
  3. Gitelson E , Hammond C , Mena J , et al.   Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines . Clin Cancer Res . 2003;9:1656–1665
  4. Juffs H , Fowler N , Saal R , et al.   B cell chronic lymphocytic leukemia cells have reduced capacity to upregulate expression of MHC class I in response to interferon-gamma . Pathology . 2004;36:69–76
  5. Williams JF , Petrus MJ , Wright JA , et al.   fas-mediated lysis of chronic lymphocytic leukemia cells (Role of type I versus type II cytokines and autologous fasL-expressing T cells) . Br J Haematol . 1999;107:99–105
  6. Foa R , Giovarelli M , Jemma C , et al.   Interleukin 2 (IL 2) and interferon-gamma production by T lymphocytes from patients with B-chronic lymphocytic leukemia (Evidence that normally released IL 2 is absorbed by the neoplastic B cell population) . Blood . 1985;66:614–619
  7. Totterman TH , Carlsson M , Simonsson B , et al.   T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease . Blood . 1989;74:786–792
  8. Tinhofer I , Marschitz I , Kos M , et al.   Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia . Blood . 1998;91:4273–4281
  9. Rezvany MR , Jeddi-Tehrani M , Osterborg A , et al.   Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia (Major perturbations are preferentially seen within the CD4 T-cell subset) . Blood . 1999;94:1063–1069
  10. Farace F , Orlanducci F , Dietrich PY , et al.   T cell repertoire in patients with B chronic lymphocytic leukemia. Evidence for multiple in vivo T cell clonal expansions . J Immunol . 1994;153:4281–4290
  11. Goolsby CL , Kuchnio M , Finn WG , et al.   Expansions of clonal and oligoclonal T cells in B-cell chronic lymphocytic leukemia are primarily restricted to the CD3(+)CD8(+) T-cell population . Cytometry . 2000;42:188–195
  12. Cantwell M, Hua T, Pappas J, et al: Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med 3:984-989.
  13. Rossi E , Matutes E , Morilla R , et al.   Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia . Leukemia . 1996;10:494–497
  14. Gorgun G , Holderried TA , Zahrieh D , et al.   Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells . J Clin Invest . 2005;115:1797–1805
  15. Scrivener S , Goddard RV , Kaminski ER , et al.   Abnormal T-cell function in B-cell chronic lymphocytic leukemia . Leuk Lymphoma . 2003;44:383–389
  16. Beyer M , Kochanek M , Darabi K , et al.   Reduced frequencies and suppressive function of CD4+ CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine . Blood . 2005;106:2018–2025
  17. Heilmann E , Witting C , Starcke A . Clinical treatment of chronic lymphatic leukemia by means of extracorporeal blood irradiation . Folia Haematol Int Mag Klin Morphol Blutforsch . 1978;105:338–341
  18. Muller CP , Treiber D , Steinke B , et al.   Enhanced antigenicity of autologous leukemia cells enriched with cholesterylhemisuccinate . Anticancer Res . 1991;11:925–930
  19. Ranheim EA , Kipps TJ . Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal . J Exp Med . 1993;177:925–935
  20. Yellin MJ , Sinning J , Covey LR , et al.   T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity . J Immunol . 1994;153:666–674
  21. Van den Hove LE , Van Gool SW , Vandenberghe P , et al.   CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules . Leukemia . 1997;11:572–580
  22. Buhmann R , Nolte A , Westhaus D , et al.   CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy (Stimulation of allogeneic versus autologous T cells generates different types of effector cells) . Blood . 1999;93:1992–2002
  23. Krackhardt AM , Harig S , Witzens M , et al.   T-cell responses against chronic lymphocytic leukemia cells (Implications for immunotherapy) . Blood . 2002;100:167–173
  24. Hoogendoorn M , Wolbers JO , Smit WM , et al.   Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators (Implications for adoptive immunotherapy) . Leukemia . 2004;18:1278–1287
  25. Kater AP , Evers LM , Remmerswaal EB , et al.   CD40 stimulation of B-cell chronic lymphocytic leukemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack . Br J Haematol . 2004;127:404–415
  26. Gricks CS , Zahrieh D , Zauls AJ , et al.   Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells . Blood . 2004;104:4002–4009
  27. Brentjens RJ , Latouche JB , Santos E , et al.   Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 . Nat Med . 2003;9:279–286
  28. Cheadle EJ , Gilham DE , Thistlethwaite FC , et al.   Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells . Br J Haematol . 2005;129:322–332
  29. Arditti FD , Aviner S , Dekel B , et al.   Eradication of B-CLL by autologous and allogeneic host nonreactive anti-third-party CTLs . Blood . 2005;105:3365–3371
  30. Bonyhadi M , Frohlich M , Rasmussen A , et al.   In vitro engagement of CD3 and CD28 corrects T cell defects in chronic lymphocytic leukemia . J Immunol . 2005;174:2366–2375
  31. Janeway CA , Sakato N , Eisen HN . Recognition of immunoglobulin idiotypes by thymus-derived lymphocytes . Proc Natl Acad Sci U S A . 1975;72:2357–2360
  32. Bogen B , Malissen B , Haas W . Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules . Eur J Immunol . 1986;16:1373–1378
  33. Campbell MJ , Carroll W , Kon S , et al.   Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits . J Immunol . 1987;139:2825–2833
  34. George AJ , Folkard SG , Hamblin TJ , et al.   Idiotypic vaccination as a treatment for a B cell lymphoma . J Immunol . 1998;141:2168–2174
  35. Kwak LW , Campbell MJ , Czerwinski DK , et al.   Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors . N Engl J Med . 1992;327:1209–1215
  36. Hsu FJ , Caspar CB , Czerwinski D , et al.   Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma—Long-term results of a clinical trial . Blood . 1997;89:3129–3135
  37. Trojan A , Schultze JL , Witzens M , et al.   Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies . Nat Med . 2000;6:667–672
  38. Harig S , Witzens M , Krackhardt AM , et al.   Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues . Blood . 2001;98:2999–3005
  39. Tao MH , Levy R . Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma . Nature . 1993;362:755–758
  40. Bendandi M , Gocke CD , Kobrin CB , et al.   Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma . Nat Med . 1999;5:1171–1177
  41. Czuczman MS , Class K , Scheinberg DA . Interleukin-4 priming enhances a target for human complement-mediated cytotoxicity of CLL . Leukemia . 1993;7:1020–1025
  42. Siegel S , Wagner A , Kabelitz D , et al.   Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies . Blood . 2003;102:4416–4423
  43. Reker S , Meier A , Holten-Andersen L , et al.   Identification of novel survivin-derived CTL epitopes . Cancer Biol Ther . 2004;3:173–179
  44. Wang Z , Zhang Y , Mandal A , et al.   The spermatozoa protein, SLLP1, is a novel cancer-testis antigen in hematologic malignancies . Clin Cancer Res . 2004;10:6544–6550
  45. Krackhardt AM , Witzens M , Harig S , et al.   Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX . Blood . 2002;100:2123–2131
  46. Spaner DE , Hammond C , Mena J , et al.   A phase I/II trial of oxidized autologous tumor vaccines during the “watch and wait” phase of chronic lymphocytic leukemia . Cancer Immunol Immunother . 2005;54:635–646
  47. Banchereau J , Steinman RM . Dendritic cells and the control of immunity . Nature . 1998;392:245–252
  48. Brossart P , Bevan MJ . Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells (Pathway of presentation and regulation by cytokines) . Blood . 1997;90:1594–1599
  49. Brossart P , Wirths S , Brugger W , et al.   Dendritic cells in cancer vaccines . Exp Hematol . 2001;29:1247–1255
  50. Nestle FO , Alijagic S , Gilliet M , et al.   Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells . Nat Med . 1998;4:328–332
  51. Thurner B , Haendle I , Roder C , et al.   Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma . J Exp Med . 1999;190:1669–1678
  52. Murphy GP , Tjoa BA , Simmons SJ , et al.   Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides (A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease) . Prostate . 1999;38:73–78
  53. Murphy GP , Tjoa BA , Simmons SJ , et al.   Phase II prostate cancer vaccine trial (Report of a study involving 37 patients with disease recurrence following primary treatment) . Prostate . 1999;39:54–59
  54. Kugler A , Stuhler G , Walden P , et al.   Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids . Nat Med . 2000;6:332–336
  55. Fong L , Hou Y , Rivas A , et al.   Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy . Proc Natl Acad Sci U S A . 2001;98:8809–8814
  56. Timmerman JM , Czerwinski DK , Davis TA , et al.   Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma (Clinical and immune responses in 35 patients) . Blood . 2002;99:1517–1526
  57. Goddard RV , Prentice AG , Copplestone JA , et al.   Generation in vitro of B-cell chronic lymphocytic leukemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumor cell lysate . Clin Exp Immunol . 2001;126:16–28
  58. Muller MR , Tsakou G , Grunebach F , et al.   Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells . Blood . 2004;103:1763–1769
  59. Goddard RV , Prentice AG , Copplestone JA , et al.   In vitro dendritic cell-induced T cell responses to B cell chronic lymphocytic leukemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids . Clin Exp Immunol . 2003;131:82–89
  60. Kokhaei P , Rezvany MR , Virving L , et al.   Dendritic cells loaded with apoptotic tumor cells induce a stronger T-cell response than dendritic cell-tumor hybrids in B-CLL . Leukemia . 2003;17:894–899
  61. Hus I , Rolinski J , Tabarkiewicz J , et al.   Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia . Leukemia . 2005;19:1621–1627
  62. Mocikat R , Selmayr M , Thierfelder S , et al.   Trioma-based vaccination against B-cell lymphoma confers long-lasting tumor immunity . Cancer Res . 1997;57:2346–2349
  63. Wahl U , Nossner E , Kronenberger K , et al.   Vaccination against B-cell chronic lymphocytic leukemia with trioma cells (preclinical evaluation) . Clin Cancer Res . 2003;9:4240–4246
  64. Takahashi S , Rousseau RF , Yotnda P , et al.   Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes . Hum Gene Ther . 2001;12:659–670
  65. Wendtner CM , Kofler DM , Theiss HD , et al.   Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors . Blood . 2002;100:1655–1661
  66. Tolba KA , Bowers WJ , Hilchey SP , et al.   Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia . Blood . 2001;98:287–295
  67. Biagi E , Dotti G , Yvon E , et al.   Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes . Blood . 2005;105:2436–2442
  68. Wierda WG , Cantwell MJ , Woods SJ , et al.   CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia . Blood . 2000;96:2917–2924
  69. Spaner DE , Hammond C , Mena J , et al.   Effect of IL-2R beta-binding cytokines on costimulatory properties of chronic lymphocytic leukemia cells (Implications for immunotherapy) . Br J Haematol . 2004;127:531–542
  70. Ehrlich P . The Croonian Lecture (“On immunity with special reference to cell life) . ” Proc R Soc . 1900;66:424–448
  71. McLaughlin P , Grillo-Lopez AJ , Link BK , et al.   Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma (Half of patients respond to a four-dose treatment program) . J Clin Oncol . 1998;16:2825–2833
  72. Byrd JC , Murphy T , Howard RS , et al.   Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity . J Clin Oncol . 2001;19:2153–2164
  73. O’Brien SM , Kantarjian H , Thomas DA , et al.   Rituximab dose-escalation trial in chronic lymphocytic leukemia . J Clin Oncol . 2001;19:2165–2170
  74. Hainsworth JD , Litchy S , Barton JH , et al.   Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (A phase II trial of the Minnie Pearl Cancer Research Network) . J Clin Oncol . 2003;21:1746–1751
  75. Keating MJ , Flinn I , Jain V , et al.   Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine (Results of a large international study) . Blood . 2002;99:3554–3561
  76. Stilgenbauer S , Dohner H . Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy . N Engl J Med . 2002;347:452–453
  77. Byrd J , Peterson B , Park K . Rituximab added to fludarabine improves response in previously untreated chronic lymphocytic leukemia (Preliminary results from CALGB 9712) . Proc Am Soc Clin Oncol . 2001;20:280a; (abstr 1116)
  78. Keating MJ , O’Brien S , Albitar M , et al.   Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia . J Clin Oncol . 2005;23:4079–4088
  79. Wierda W , O’Brien S , Wen S , et al.   Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia . J Clin Oncol . 2005;23:4070–4078
  80. Kennedy B , Rawstron A , Carter C , et al.   Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia . Blood . 2002;99:2245–2247
  81. Rai KR , Byrd JC , Peterson B , et al.   A phase II trial of fludarabine followed by alemtuzumab (CAMPATH-1H) in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease (Cancer and Leukemia Group B (CALGB) study 19901) . Blood . 2002;100:205a; (abstr 772)
  82. Faderl S , O’Brien S . Combined use of alemtuzumab and rituximab in patients with relapsed or refractory chronic lymphoid malignancies (An update of the M.D. Anderson experience) . Blood . 2002;100:206a; (abstr 775)
  83. Reusch U , Le Gall F , Hensel M , et al.   Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells . Int J Cancer . 2004;112:509–518
  84. Kreitman RJ , Wilson WH , Bergeron K , et al.   Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia . N Engl J Med . 2001;345:241–247
  85. LeMaistre CF , Meneghetti C , Rosenblum M , et al.   Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor . Blood . 1992;79:2547–2554
  86. Fleming DR , Powell BL , Patrick CL . Diphtheria fusion protein ONTAK therapy of patients with fludarabine refractory chronic lymphocytic leukemia . Proc Am Soc Clin Oncol . 2002;19:268a; (abstr 1071)
  87. Jarque I , Palau J , Sanz GF , et al.   Delayed complete response after allogeneic bone marrow transplantation in chronic lymphocytic leukemia . Blood . 1993;82:1036–1038
  88. Mehta J , Powles R , Singhal S , et al.   Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease (Possible role of graft-versus-leukemia) . Bone Marrow Transplant . 1996;17:371–375
  89. Rondon G , Giralt S , Huh Y , et al.   Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia . Bone Marrow Transplant . 1996;18:669–672
  90. Michallet M , Archimbaud E , Bandini G , et al.  European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry   HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia . Ann Intern Med . 1996;124:311–315
  91. Ritgen M , Stilgenbauer S , von Neuhoff N , et al.   Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status (Implications of minimal residual disease measurement with quantitative PCR) . Blood . 2004;104:2600–2602
  92. Ritgen M , Dreger P , Humpe A , et al.   Quantitative PCR demonstrates effective graft versus leukemia activity after allogeneic stem cell transplantation using reduced intensity conditioning in patients with chronic lymphocytic leukemia . Blood . 2002;100:854a; (abstr)
  93. Khouri IF , Przepiorka D , van Besien K , et al.   Allogeneic blood or marrow transplantation for chronic lymphocytic leukemia (Timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease) . Br J Haematol . 1997;97:466–473
  94. Dreger P , van Biezen A , Brand R . Reduced-intensity conditioning lowers treatment-related mortality (TRM) of allogeneic stem cell transplantation (SCT) for CLL (A retrospective study on 448 patients) . Blood . 2003;102:197a; (abstr)
  95. Giralt S , Thall PF , Khouri I , et al.   Melphalan and purine analog-containing preparative regimens (Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation) . Blood . 2001;97:631–637
  96. Khouri IF , Keating M , Korbling M , et al.   Transplant-lite (Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies) . J Clin Oncol . 1998;16:2817–2824
  97. Schetelig J , Thiede C , Bornhauser M , et al.  The Cooperative German Transplant Study Group   Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation . J Clin Oncol . 2003;21:2747–2753
  98. Dreger P , Brand R , Hansz J , et al.   Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning . Leukemia . 2003;17:841–848
  99. Sorror ML , Maris MB , Sandmaier BM , et al.   Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia . J Clin Oncol . 2005;23:3819–3829
  100. Morris E , Thomson K , Craddock C , et al.   Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma . Blood . 2004;104:3865–3871

PII: S0093-7754(05)00506-3

doi: 10.1053/j.seminoncol.2005.12.012

Seminars in Oncology
Volume 33, Issue 2 , Pages 220-229 , April 2006

Article Tools

* Image Usage & Resolution